Guangyang Weng

机构：Shenzhen Second People's Hospital · ORCID：0000-0002-7923-8972

发表论文 39 篇 · 总被引 166 次 · h-index 7

代表论文

• Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study (2024 · Clinical Cancer Research · 被引 12)
• Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia (2024 · Journal of Cancer Research and Clinical Oncology · 被引 8)
• Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study (2025 · British Journal of Haematology · 被引 3)
• Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy (2024 · Cancer Medicine · 被引 3)
• Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study (2023 · Annals of Hematology · 被引 3)
• Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study (2023 · Blood · 被引 2)